Video

VIDEO: ASCO Breast Cancer Symposium final wrap-up with Dr. Hope S. Rugo


 

AT THE ASCO BREAST CANCER SYMPOSIUM

References

SAN FRANCISCO – Can we figure out who doesn’t need excision of atypical ductal hyperplasia and intraepithelial neoplasia? Should we screen all women with low–estrogen receptor positivity (1%-9%) for BRCA mutations? Dr. Hope S. Rugo discusses these questions and others that came up during the final sessions at the breast cancer symposium sponsored by the American Society of Clinical Oncology.

The meeting closed out with discussions of evolving standards in the treatment of breast cancer, how to apply these standards to clinical practice, and talks on reversing hormone resistance, including new agents to improve response to hormone therapy.

Dr. Rugo, director of the Breast Oncology Clinical Trials Program at the University of California, San Francisco, also summarizes data presented in the final presentations, including results from a randomized phase II trial of a GP2 vaccine in the adjuvant setting for high-risk breast cancer patients, suggesting that it may reduce recurrence rates in some women with HER2-positive cancer. “It’s very encouraging because we’ve been sort of barking up the vaccine alley for a long, long time and not gotten anywhere. I think it’s quite encouraging data,” she says.

Dr. Rugo disclosed financial associations with Genomic Health, Plexxikon, Merck, and Novartis. She is on the scientific advisory board of Galena Biopharma, which is developing the breast cancer vaccines.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

sboschert@frontlinemedcom.com

On Twitter @sherryboschert

Recommended Reading

Moving beyond the one-size-fits-all formula for breast cancer treatments
MDedge Hematology and Oncology
For advanced HER2-negative breast cancer, no best treatment
MDedge Hematology and Oncology
VIDEO: NCI’s Dr. Steven Rosenberg talks TILs in breast cancer and much more
MDedge Hematology and Oncology
No mortality benefit from bilateral mastectomy, vs. breast-conserving surgery with radiation
MDedge Hematology and Oncology
Researchers deem tumor-infiltrating lymphocytes valid prognostic biomarker in TNBC
MDedge Hematology and Oncology
Locoregional recurrence of breast cancer less likely after neoadjuvant complete response
MDedge Hematology and Oncology
PIK3CA mutations linked to lower pCR rates in women with HER2-positive breast cancer
MDedge Hematology and Oncology
VIDEO: Complications increase with bilateral mastectomy and reconstruction
MDedge Hematology and Oncology
VIDEO: Breast cancer symposium take-home messages, Day 1
MDedge Hematology and Oncology
VIDEO: Dr. Hope S. Rugo on breast cancer symposium hot topics, Day 2
MDedge Hematology and Oncology